Ma YL - Search Results

1

Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide.

Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A, Sato M. Chen P, et al. Among authors: ma yl. J Bone Miner Res. 2007 Jun;22(6):841-8. doi: 10.1359/jbmr.070310. J Bone Miner Res. 2007. PMID: 17352652 Free article.

2

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee WS, Turner CH, Sato M. Ma YL, et al. J Bone Miner Res. 2002 Dec;17(12):2256-64. doi: 10.1359/jbmr.2002.17.12.2256. J Bone Miner Res. 2002. PMID: 12469920 Free article.

3

Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.

Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH. Sato M, et al. Among authors: ma yl. J Bone Miner Res. 2004 Apr;19(4):623-9. doi: 10.1359/JBMR.040112. Epub 2004 Jan 12. J Bone Miner Res. 2004. PMID: 15005850 Free article.

4

Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Schmidt A, Jee WS, Sato M. Ma YL, et al. J Bone Miner Metab. 2005;23 Suppl:62-8. doi: 10.1007/BF03026325. J Bone Miner Metab. 2005. PMID: 15984416

5

New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M. Ma YL, et al. Endocrinology. 2003 May;144(5):2008-15. doi: 10.1210/en.2002-221061. Endocrinology. 2003. PMID: 12697709

6

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL. Kulkarni NH, et al. Among authors: ma yl. J Bone Miner Res. 2006 Jun;21(6):910-20. doi: 10.1359/jbmr.060316. J Bone Miner Res. 2006. PMID: 16753022 Free article.

7

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.

Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL. Sato M, et al. Among authors: ma yl. J Bone Miner Res. 2010 Jun;25(6):1326-36. doi: 10.1002/jbmr.15. J Bone Miner Res. 2010. PMID: 20200930 Free article.

8

Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.

Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M. Ma YL, et al. Endocrinology. 2011 May;152(5):1767-78. doi: 10.1210/en.2010-1112. Epub 2011 Feb 22. Endocrinology. 2011. PMID: 21343258

9

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.

Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan JJ. Ma YL, et al. Bone. 2014 Feb;59:139-47. doi: 10.1016/j.bone.2013.11.011. Epub 2013 Nov 20. Bone. 2014. PMID: 24269280 Clinical Trial.

10

Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment.

Sato M, Ma YL, Hock JM, Westmore MS, Vahle J, Villanueva A, Turner CH. Sato M, et al. Among authors: ma yl. J Pharmacol Exp Ther. 2002 Jul;302(1):304-13. doi: 10.1124/jpet.302.1.304. J Pharmacol Exp Ther. 2002. PMID: 12065731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

700 results

Search Page

Filters